综述：转移性结直肠癌中贝伐珠单抗相关非手术和手术严重不良事件的发生率和临床意义。
Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.
机构信息
Department of Surgery, Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
出版信息
Eur J Surg Oncol. 2011 Sep;37(9):737-46. doi: 10.1016/j.ejso.2011.06.004. Epub 2011 Jul 20.
OBJECTIVE AND BACKGROUND
This review describes the extent, frequency and clinical importance of Bevacizumab(BV)-related serious adverse events (SAE) after surgery, during or after chemotherapy with BV in patients with metastatic colorectal cancer (mCRC).
METHODS
Detailed PubMed search in November 2009.
RESULTS
Addition of BV to first- or second-line chemotherapy in patients with mCRC results in a statistically significant benefit in OS, PFS and RR. Addition of BV to chemotherapy causes no clinically relevant aggravation of SAE and seems safe with the primary tumor still in situ. The risk of emergency surgery due to BV-related SAE is estimated 2.0%. SAE rate is low if a time to surgery of 5-6 weeks is respected. The majority of SAE are wound healing complications. Bleeding and GI perforation occur infrequently, even following major surgery after BV-treatment. Major surgery during the course of BV-treatment results in an SAE rate of 1.3-2.7%. Postoperatively, a period of minimally 28 days should be respected before starting BV.
CONCLUSION
Reported rates of BV-related SAE in relationship to surgery are low.
目的和背景
本综述描述了转移性结直肠癌（mCRC）患者在手术后、化疗期间或化疗后使用贝伐珠单抗（BV）时，与 BV 相关的严重不良事件（SAE）的程度、频率和临床重要性。
方法
2009 年 11 月详细的 PubMed 搜索。
结果
在 mCRC 患者的一线或二线化疗中添加 BV 可显著改善 OS、PFS 和 RR。BV 联合化疗不会导致 SAE 的临床相关加重，并且对于原发肿瘤仍位于原位的患者来说似乎是安全的。由于 BV 相关 SAE 而需要紧急手术的风险估计为 2.0%。如果尊重 5-6 周的手术时间，SAE 发生率较低。大多数 SAE 是伤口愈合并发症。即使在 BV 治疗后进行大手术后，出血和 GI 穿孔也很少发生。在 BV 治疗过程中进行大手术，SAE 发生率为 1.3-2.7%。术后，应至少尊重 28 天才能开始 BV。
结论
报告的与手术相关的 BV 相关 SAE 发生率较低。
Zotero 插件